Hovinga et al22 recently analyzed time to progression in GBM patients treated with Bev and reported that epidermal growth factor receptor amplification and the classical subtype are associated with a poor response to Bev in recurrent GBM. This evidence concerns the gene EGFR and glioblastoma.